Pulmonary Absorption Enhancement of Salmon Calcitonin

References

• Ahsan, F., Arnold, J.J., Meezan, E. and Pillion, D.J. (2001) “Mutual inhibition of the insulin absorption enhancing properties of dodecyl maltoside and dimethyl cyclodextrin following nasal administration”, Pharm. Res. 18, 608–614.
   Google Scholar
• Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K. and Watson, J.D. (1989) “Cell adhesion, cell junctions and the Extracellular matrix”, Molecular Biology of the Cell (Gerland, New York), pp. 791–836.
   Google Scholar
• Audus and Thomas, J.R. (1993) Biological barriers to protein drug delivery Pharmaceutical Biotechnology, (Plenum Press, New York and London) Vol. 4, pp. 23–50.
   Google Scholar
• Davis, S.S. (1999) “Delivery of peptide and non-peptide drugs through the respiratory tract”, Pharm. Sci. Technol. Today 12, 450–459.
   Google Scholar
• Deftos, L.J., Nolan, J.J., Seely, B.L., Clopton, P.L., Cote, G.J., Whitham, C.L., Florex, L.J., Christensen, T.A. and Hill, M.R. (1997) “Intrapulmonary drug delivery of Salmon Calcitonin”, Calcif. Tissue Int. 61, 345–347.
   PubMed Web of Science ®Google Scholar
• Devore, J.L. and Farnum, N.R. (1999) Applied Statistics for Engineers and Scientists (Duxbury Press/International Thomson Publishing Inc.), pp 394–398.
   Google Scholar
• Enna, S.J. and Schanker, L.S. (1972) “Absorption of saccharides and urea from the rat lung”, Am. J. Physiol. 222, 409–414.
   Web of Science ®Google Scholar
• Gordon, G.S., Moses, A.C., Silver, R.D., Flier, J.S. and Carey, M.C. (1985) “Nasal absorption of insulin enhancement by bile salts”, Proc. Natl Acad. Sci. USA 82, 7419–7423.
   PubMed Web of Science ®Google Scholar
• Hochman, J. and Artursson, P. (1994) “Mechanism of absorption enhancement and tight junction regulation”, J. Control. Release 29, 253–267.
   Web of Science ®Google Scholar
• Khan, M.J., Lakshminarayanaiah, N., Trotman, B.W., Chun, P., Kaplan, S.A. and Margulies, C. (1982) “Calcium binding and bile salt structure”, Hepatology 2, 732.
   Web of Science ®Google Scholar
• Kobayashi, S., Kondo, S. and Juni, K. (1994) “Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers”, Pharm. Res. 11, 1239–1243.
   Google Scholar
• Kobayashi, S., Kondo, S. and Juni, K. (1996) “Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats”, Pharm. Res. 13, 80–83.
   Google Scholar
• Komada, F., Iwakawa, S., Yamamoto, N., Sakakibara, H. and Okumura, K. (1994) “Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung”, J. Pharm. Sci. 83, 863–867.
   PubMed Web of Science ®Google Scholar
• Lee, V.H.L. (1990) “Protease inhibitors and penetration enhancers as approaches to modify peptide absorption”, J. Control. Rel. 13, 213–223.
   Web of Science ®Google Scholar
• Lee, K.C., Lee, Y.J., Song, H.M., Chun, C.J. and Oeluca, P.P. (1992) “Degradation of synthetic salmon calcitonin in aqueous solution”, Pharm. Res. 9, 1521–1523.
   Google Scholar
• Lee, K.C., Soltis, E.E., Newman, P.S., Burton, K.W., Mehta, R.C. and DeLuca, P.P. (1991) “In vivo assessment of salmon calcitonin sustained release from biodegradable microspheres”, J. Control. Release 17, 199–206.
   Web of Science ®Google Scholar
• Maini, M., Bozzi, M., Brignoli, et al. (1995) “Calcitonin nasal spray in osteoporosis: short and long-term effects of various treatment regimens”, Minerva Med. 86, 121–127.
   Google Scholar
• Martin, Mc.C., Hutchinson, L.E.F., Hyde, R. and Peters, G.E. (1987) “Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity”, J. Pharm. Sci. 70, 535–540.
   Google Scholar
• Marttin, E., Verhoef, J.C. and Merkus, F.W.H.M. (1997) “Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs”, J. Drug Target. 6, 17–36.
   Web of Science ®Google Scholar
• Munoz, B.Y., Domingo, A.R. and Minguella, J.F. (2000) “Calcitonin: Osteoporosis treatment and prevention”, Drugs Today 36(Suppl. D), 13–25.
   Google Scholar
• Patton, J.S., Trinchero, P. and Platz, R.M. (1994) “Bioavailability of pulmonary delivered peptide and protein: interferon alpha, calcitonin and parathyroid hormones”, J. Control. Rel. 28, 79–85.
   Web of Science ®Google Scholar
• Patton, J.S., Bukar, J. and Nagarajan, S. (1999) “Inhaled insulin”, Adv. Drug Delivery Rev. 35, 235–247.
   PubMed Web of Science ®Google Scholar
• Physician Desk Reference, 51st Edition (1997). Medical Economics, Montvalc, NJ, pp. 2403–2405.
   Google Scholar
• Rico, H., Revilla, M. and Hernandez, M. (1995) “Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study”, Cacif. Tissue Int. 56, 181–185.
   PubMed Web of Science ®Google Scholar
• Seeman, E., Tsalamandris, C. and Bass, S. (1995) “Present and future of osteoporosis therapy”, Bone 87, 203–209.
   Google Scholar
• Silverman, S., Chesnut, C. and Andriano, K. (1998) “Salmon Calcitonin nasal spray reduces risk of vertebral fractures(s) in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5-year worldwide data of the PROOF study”, Bone 23(Suppl. 5), S 174.
   Google Scholar
• Yamomoto, A., Hayakawa, E. and Lee, H.L. (1990) “Insulin and pro- insulin proteolysis in mucosal homogenate of the albino rabbit; Implications in peptide delivery from non-oral routes”, Life Sci. 47, 2465–2474.
   PubMed Web of Science ®Google Scholar